Back to Peptides

Ara 290

Extensively Studied

Tissue-Protective Peptide | Innate Repair Receptor Agonist

Dose 4 mg daily
Frequency Once daily
Cycle 28 days
Storage Lyophilized: 2-8°C refrigerated, protect from light. Reconstituted: use immediately or refrigerate up to 24 hours
Accumulation Plotter

Sponsor this page

This spot is open on the Ara 290 page.

Be the featured Ara 290 source Email us about sponsoring this compound.
Sponsorships never affect our research into compounds. All of our research stays 100% independent.

Ara 290 is an engineered 11-amino acid peptide activating the Innate Repair Receptor (IRR) to provide tissue-protective effects without red blood cell stimulation. Has FDA Orphan Drug status.

Mechanism of Action

Activates IRR through EPOR/β-common receptor complex, triggering tissue-protective signaling without erythropoietic effects.

Key Benefits

  • Proven tissue protection
  • Nerve regeneration
  • Anti-inflammatory effects
  • Excellent safety profile in clinical trials
Molecular Weight
1,257 Da
Chain Length
11 amino acids
Type
Engineered peptide
Amino Acid Sequence
One-letter: ?ELERALNSS
H₂N
H
? 1
O ‖ C
N
E 2
O ‖ C
N
L 3
O ‖ C
N
E 4
O ‖ C
N
R 5
O ‖ C
N
A 6
O ‖ C
N
L 7
O ‖ C
N
N 8
O ‖ C
N
S 9
O ‖ C
N
S 10
COOH
pGl
1

pGlu

Position 1

Glu
2

Glutamic Acid

Position 2

Leu
3

Leucine

Position 3

Glu
4

Glutamic Acid

Position 4

Arg
5

Arginine

Position 5

Ala
6

Alanine

Position 6

Leu
7

Leucine

Position 7

Asn
8

Asparagine

Position 8

Ser
9

Serine

Position 9

Ser
10

Serine

Position 10

N-terminus C-terminus
Hydrophobic
Polar
Positive (+)
Negative (-)
Modified

Neuroprotection

  • Peripheral Nerve Regeneration

    23% increase in corneal nerve fiber area with sustained pain improvement.

  • Diabetic Neuropathy Treatment

    Nerve regeneration and metabolic improvements in Type 2 diabetes patients.

  • CNS Protection

    Crosses blood-brain barrier for stroke and TBI neuroprotection.

Tissue Repair

  • Wound Healing

    Improves epithelialization and angiogenesis via VEGF upregulation.

  • Cardiovascular Protection

    Reduces infarct size in myocardial infarction models.

  • Anti-Aging Effects

    Maintains cardiac function in aging models.

Anti-Inflammatory

  • Cytokine Reduction

    Reduces TNF-α, IL-6, and IL-12 production.

  • IBD Support

    Reduces colitis severity in animal models.

  • Transplant Protection

    Improves graft survival and reduces rejection.

Primary clinical administration route with proven efficacy.

GoalDoseFrequencyRoute
Neuropathy Treatment4 mg dailyOnce dailySubQ
Tissue Protection1-8 mg dailyOnce dailySubQ
Acute Intervention2 mg3x weeklyIV

Reconstitution Instructions

Materials Needed:
  • Ara 290 lyophilized powder (4 mg vial)
  • Sterile water for injection
  • Sterile syringes and needles
  • Alcohol swabs
  • Light protection
  1. 1 Allow vial to reach room temperature (15-20 minutes)
  2. 2 Clean vial top with alcohol swab
  3. 3 Slowly inject 1 mL sterile water
  4. 4 Gently swirl to dissolve (no vigorous shaking)
  5. 5 Slight cloudiness is normal
  6. 6 Use immediately or refrigerate up to 24 hours
  7. 7 Protect from light
  8. 8 Rotate injection sites
BPC-157

Complementary tissue repair pathways may enhance wound healing.

synergistic
TB-500

Combined mechanisms enhance recovery from injury.

synergistic
Thymosin Beta-4

No known interactions; different mechanisms for tissue protection.

compatible
EPO

Clinical trials exclude EPO use within 2 months due to receptor interference.

avoid
NAD+

Both affect cellular metabolism; monitor for additive effects.

monitor
Semaglutide

No adverse interactions in clinical trials with GLP-1 agonists.

compatible
Growth Hormone

Both affect tissue repair; requires monitoring for excessive growth factor activity.

monitor
Anti-TNF Biologics

6-month washout required before Ara 290 to avoid immune interactions.

avoid
Week 1-2

Initial anti-inflammatory effects and mild pain symptom improvement

Week 2-4

Progressive nerve regeneration, improved tissue healing markers

Week 4-6

Peak therapeutic effects, maximum nerve fiber density improvements

Month 2-6

Long-lasting benefits via molecular switch effect

Common Side Effects

  • Excellent safety profile in clinical trials with no serious drug-related adverse events

Stop Signs - Discontinue if:

  • Severe injection site reactions
  • Unexpected blood count changes
  • Allergic reaction signs
  • Worsening of underlying condition
  • New neurological symptoms
  • Any serious adverse events

Contraindications

  • Recent anti-TNF therapy (within 6 months)
  • EPO use (within 2 months)
  • Pregnancy
  • BMI > 34 kg/m²

Good Signs

  • Pharmaceutical grade manufacturing with GMP conditions
  • Proper peptide sequence verification - correct 11-amino acid sequence with N-terminal pyroglutamate
  • Sterile lyophilized powder with proper freeze-drying
  • Clinical batch documentation - Purity >95%, endotoxin <1 EU/mg, sterility verified

Warning Signs

  • Light-sensitive formulation - requires protection during storage and use

Bad Signs

  • Cloudy or discolored solution indicates degradation; should be clear to slightly cloudy
  • Sarcoidosis Neuropathy Phase 2b Trial
    (2017)

    64 patients, 1-8 mg SC daily for 28 days: 23% increase in corneal nerve fiber area at 4 mg dose.

  • Type 2 Diabetes Neuropathy Phase 2
    (2015)

    48 patients, 4 mg SC daily for 28 days: Sustained HbA1c improvement and nerve regeneration.

  • Diabetic Macular Edema Pilot Study
    (2020)

    9 patients, 4 mg SC daily for 12 weeks: Improved quality of life; good safety profile.

  • Myocardial Infarction Protection Study
    (2012)

    Preclinical mouse model, 24 μg/kg IV single dose: Reduced infarct size and improved survival.

  • Stroke Neuroprotection Research
    (2011)

    Rat stroke model, 300 μg/kg IV single dose: Reduced stroke volume; BBB penetration confirmed.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.